RNADD is developing a very low-cost molecular diagnostic testing platform for point-of-care diagnosis of infectious diseases to disrupt and democratize molecular testing. Our strategy is to leverage our proprietary Electrochemical and Antisense Oligonucleotide (ASO) molecular testing platform across multiple infectious disease categories including Women’s Health, Respiratory Diseases (Covid-19, Flu A, RSV, Strep A), STDs, and future Pandemics, etc. Our multiplexing molecular testing platform has the accuracy, sensitivity, and specificity of the gold standard RT-PCR but with significantly faster speed and at a cost similar to antigen tests. Our multiplexing platform provides simultaneous test results in 5-minutes (+75% time savings) without any sample amplification or isolation.

RNADD has the exclusive global IP license to the technology and has completed the technology transfer from the University of Maryland-Baltimore to our commercial lab development partner. RNADD has attracted both a world-class and very experienced management team lead by Chairman, Allan Oberman, CEO of Apotex (Canada’s largest pharmaceutical company) and President, John Erickson, ex-J&J and Abbott Executive. The RNADD Board of Directors includes Dr. Patrice Alibert ex-Becton Dickenson VP of Molecular Diagnostics and Ex-CEO and President of GenePOC, Mike Kaufmann, former CEO of Cardinal Health and Richard Ganz, CEO of OmniSonics Medical Technologies.


  • Molecular Diagnostic Platform for Point of Care (POC): Urgent Care Centers, Pharmacies, Professional Doctors Offices, Emergency Departments, Nursing Homes, Airports, Offices, Warehouses, Sports Stadiums, and other high traffic venues.

  • Multiplexed Platform: Concurrent assays for Women’s Health, Respiratory (COVID-19, Flu A, RSV, Strep A), STD’s and future pandemics.

  • Fast Time to Result: – 5-minutes with Accuracy, Sensitivity and Specificity similar to Gold Standard RT-PCR testing.No amplification or isolation required.

  • Low Cost, Attractive Economics to all Stakeholders: Assay costs lower than PCR and comparable to Lateral Flow Assays.

  • Ease of Use: No special technical training, technician or additional space needed to perform test.

  • Actionable Results: “Rule In and/or Rule Out” diagnosis for immediate intervention that improves treatment time and efficacy of Rx.

RNADD Overview


Large Addressable Market

Designed to meet the demands of rapidly growing Urgent Care and Physician Office Lab markets devoid of highly accurate diagnostics with rapid turnaround times

Deep Industry Experience

Expert management team & well-defined product development roadmap

Intellectual Property

IP portfolio estate protects company’s technology & positions RNADD for expansion

Applications & Uses

Urgent Care
Dr Offices
Emergency Dept
Nursing Homes
High Traffic Sites

Exclusive Global License